Research data suggests how life sciences companies will face many industry changes during the next ten years.  Some of these changes include globalization increases, widespread restructuring, big layoffs, outsourcing of jobs and services, rise of emerging markets, growth of the generic drug market, and more.  Additionally, bio/pharma firms expect >50% of their revenues by 2015 will come from products and services that are not offered today according to a recent industry survey of life sciences senior executives.  In light of these industry changes and this recent survey statistic, executives need successful strategies and tools to help their organizations manage change in the marketplace, maintain a strong pipeline of products and services, remain profitable, and sustain a high reputation. 

This Executive Summit will discuss the business issues most pertinent to life sciences executives in an interactive and information-sharing environment.  Through stimulating discussion, participants will enhance their problem-solving abilities and productivity to initiate more collaboration and innovation back at the office.  Industry experts and forward-thinkers will present case studies of successful business models that have expanded R&D investments in emerging markets, diversified product/service portfolios, developed new partner/alliance/collaboration models, implemented novel approaches toward product commercialization, and more. 

Audience Criteria

The Executive Summit on Strategy and Innovation is open to qualified attendees only - directors and higher from pharmaceutical and biotechnology organizations; senior faculty at research universities and institutes; government agencies, and Summit sponsors.  Participants of the Summit are an elite group of individuals that are carefully screened to ensure that all in attendance meet the criteria necessary to be included. 

Agenda topics include:

Improving R&D Efficiencies
Daniel B. Kassel, Ph.D., Vice President, Analytical Sciences and DMPK, Takeda San Diego, Inc. (Invited)

Drug Repurposing Strategy: Extending the Life of Blockbuster Products with Synergistic Repurposed-drug Combinations
John Maki, President and Chief Executive Officer, Vicus Therapeutics

NanoMedicine: Next Generation Blockbusters
Arkesh Mehta, Ph.D., Chief Executive Officer, Chikujee Therapeutics

Improving Pharmaceutical R&D Productivity to Sustain Value for Stakeholders
Aditya R. Das, Ph.D., M.B.A., Director, Business Development, AAIPharma, Inc.

Cost-risk-value Optimization – A New Model that Leads to Greater R&D Efficiency
Declan Doogan, M.D., Head of Research and Development, Amarin Corporation

Title To Be Announced
Bryan Walser, M.D., J.D., Chief Executive Officer, Perlegen Sciences

Title To Be Announced
Bruce Keyt, Ph.D., Vice President Research and Chief Technology Officer, Trellis Bioscience

Title To Be Announced
Richard Wagner, Ph.D., President and Chief Executive Officer, SRU Biosystems

Strategies and Novel Approaches toward Product Line Extension
Dongzhou J. Liu, Ph.D., M.Sc., M.B.A., Assistant Director, New Products R&D, GlaxoSmithKline

Diversification of Product Portfolio
Mauri Okamoto-Kearney, Vice President, Product Development & New Product Planning, KAI Pharmaceuticals, Inc.

R&D in Emerging Countries
Julio Camps, M.D., Director of Latin America Development Operations, Amgen (invited)

Adapting an Organization to Focus on Innovation& IP Management
Jochen Hurlebaus, Ph.D., MBA, Director, Innovation and IP Management, Roche Diagnostics GmbH

For questions or suggestions about the meeting, please contact:
Cindy Crowninshield
Cambridge Healthtech Institute
Tel: 781-354-0120
email: ccrowninshield@healthtech.com

For sponsorship and exhibit sales information, please contact:
Arnold Wolfson
Cambridge Healthtech Institute
Phone: 781-972-5431
Email: awolfson@healthtech.com